IDEXX LABORATORIES INC /DE Supplier Finance Program Obligation Decrease Settlement
IDEXX LABORATORIES INC /DE (IDXX) reported Supplier Finance Program Obligation Decrease Settlement of $13.83 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Payables and Accruals
us-gaap:SupplierFinanceProgramObligationDecreaseSettlement · last filed 2026-08-04
- IDEXX LABORATORIES INC /DE supplier finance program obligation decrease settlement for the quarter ending 2026-06-30 was $13.83M, a 14.92% decline year-over-year.
- IDEXX LABORATORIES INC /DE supplier finance program obligation decrease settlement for the quarter ending 2026-03-31 was $12.53M, a 1.83% increase year-over-year.
- IDEXX LABORATORIES INC /DE supplier finance program obligation decrease settlement for the quarter ending 2025-12-31 was $11.99M, a 0.71% increase year-over-year.
- IDEXX LABORATORIES INC /DE supplier finance program obligation decrease settlement for the quarter ending 2025-09-30 was $15.64M, a 4.49% increase year-over-year.
- IDEXX LABORATORIES INC /DE supplier finance program obligation decrease settlement for fiscal 2025 was $56.19M, a 11.25% increase from fiscal 2024.
- IDEXX LABORATORIES INC /DE supplier finance program obligation decrease settlement for fiscal 2024 was $50.51M, a 7.75% increase from fiscal 2023.
- IDEXX LABORATORIES INC /DE supplier finance program obligation decrease settlement for fiscal 2023 was $46.88M, a 12.44% decline from fiscal 2022.
- IDEXX LABORATORIES INC /DE supplier finance program obligation decrease settlement for fiscal 2022 was $53.54M.
| Period end | Supplier Finance Program Obligation Decrease Settlement 3 month | Supplier Finance Program Obligation Decrease Settlement 6 month | Supplier Finance Program Obligation Decrease Settlement 9 month | Supplier Finance Program Obligation Decrease Settlement 12 month |
|---|---|---|---|---|
| 2026-06-30 | $13.83M 10-Q · filed 2026-08-04 | $26.36M 10-Q · filed 2026-08-04 | $38.35M derived: sum of 3 quarters · filed 2026-08-04 | $53.99M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $12.53M 10-Q · filed 2026-05-05 | $24.52M derived: sum of 2 quarters · filed 2026-05-05 | $40.16M derived: sum of 3 quarters · filed 2026-05-05 | $56.42M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $11.99M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $27.64M derived: sum of 2 quarters · filed 2026-02-20 | $43.89M derived: sum of 3 quarters · filed 2026-08-04 | $56.19M 10-K · filed 2026-02-20 |
| 2025-09-30 | $15.64M 10-Q · filed 2025-11-03 | $31.90M derived: sum of 2 quarters · filed 2026-08-04 | $44.20M 10-Q · filed 2025-11-03 | $56.11M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $16.26M 10-Q · filed 2026-08-04 | $28.56M 10-Q · filed 2026-08-04 | $40.47M derived: sum of 3 quarters · filed 2026-08-04 | $55.44M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $12.30M 10-Q · filed 2026-05-05 | $24.21M derived: sum of 2 quarters · filed 2026-05-05 | $39.18M derived: sum of 3 quarters · filed 2026-05-05 | $51.09M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $11.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $26.88M derived: sum of 2 quarters · filed 2026-02-20 | $38.79M derived: sum of 3 quarters · filed 2026-02-20 | $50.51M 10-K · filed 2026-02-20 |
| 2024-09-30 | $14.97M 10-Q · filed 2025-11-03 | $26.88M derived: sum of 2 quarters · filed 2025-11-03 | $38.60M 10-Q · filed 2025-11-03 | $48.45M derived: sum of 4 quarters · filed 2025-11-03 |
| 2024-06-30 | $11.91M 10-Q · filed 2025-08-04 | $23.63M 10-Q · filed 2025-08-04 | $33.49M derived: sum of 3 quarters · filed 2025-08-04 | $40.36M derived: sum of 4 quarters · filed 2025-08-04 |
| 2024-03-31 | $11.72M 10-Q · filed 2025-05-01 | $21.58M derived: sum of 2 quarters · filed 2025-05-01 | $28.45M derived: sum of 3 quarters · filed 2025-05-01 | $42.94M derived: sum of 4 quarters · filed 2025-05-01 |
| 2023-12-31 | $9.85M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-21 | $16.73M derived: sum of 2 quarters · filed 2025-02-21 | $31.21M derived: sum of 3 quarters · filed 2025-02-21 | $46.88M 10-K · filed 2025-02-21 |
| 2023-09-30 | $6.88M 10-Q · filed 2024-10-31 | $21.36M derived: sum of 2 quarters · filed 2024-10-31 | $37.03M 10-Q · filed 2024-10-31 | $46.42M derived: sum of 4 quarters · filed 2024-10-31 |
| 2023-06-30 | $14.48M 10-Q · filed 2024-08-06 | $30.15M 10-Q · filed 2024-08-06 | $39.55M derived: sum of 3 quarters · filed 2024-08-06 | $55.32M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $15.67M 10-Q · filed 2024-05-01 | $25.06M derived: sum of 2 quarters · filed 2024-05-01 | $40.84M derived: sum of 3 quarters · filed 2024-05-01 | $56.45M derived: sum of 4 quarters · filed 2024-05-01 |
| 2022-12-31 | $9.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $25.17M derived: sum of 2 quarters · filed 2024-02-22 | $40.79M derived: sum of 3 quarters · filed 2024-02-22 | $53.54M 10-K · filed 2024-02-22 |
| 2022-09-30 | $15.77M 10-Q · filed 2023-11-01 | $31.39M derived: sum of 2 quarters · filed 2023-11-01 | $44.14M 10-Q · filed 2023-11-01 | |
| 2022-06-30 | $15.62M 10-Q · filed 2023-08-01 | $28.37M 10-Q · filed 2023-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Lantheus Holdings, Inc. (LNTH) | United States | $6.510B | 26.31 |
| NEOGEN CORP (NEOG) | United States | $2.979B | -247.49 |
| Celldex Therapeutics, Inc. (CLDX) | United States | $2.471B | -9.72 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |